GlassScriptPhysician profile
Ashley N Turner
NPI 1952876518
$2,767.41
in general payments reported to CMS, 2019-2025
22 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.28 · 2022: $363 · 2023: $639 · 2024: $551 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.58 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $737.96 | 2024-2025 | Tyvaso, Remodulin, Remodulin |
| Abbvie INC. | $580.97 | 2022-2025 | |
| Veloxis Pharmaceuticals, INC. | $309.04 | 2021-2023 | Envarsus |
| Actelion Pharmaceuticals US, INC. | $198.89 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $174.50 | 2023-2025 | Livtencity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.72 | 2022-2024 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $109.53 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.04 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.64 | 2025 | Jascayd, Ofev |
| Paratek Pharmaceuticals, INC. | $60.39 | 2024-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $47.26 | 2025 | |
| Astellas Pharma US INC | $33.42 | 2025 | Cresemba |
| Melinta Therapeutics, LLC | $33.37 | 2025 | Rezzayo |
| Ani Pharmaceuticals, INC. | $30.94 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $24.27 | 2023 | Soliris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $22.30 | 2023 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $21.55 | 2024 | Farxiga |
| Verona Pharma, INC. | $20.87 | 2025 | Ohtuvayre |
| Apellis Pharmaceuticals, INC. | $19.51 | 2025 | Empaveli |
| Stryker Corporation | $19.39 | 2023 | Spy-Phi System |
| La Jolla Pharmaceutical Company | $18.19 | 2025 | Giapreza |
| Invivyd INC | $16.66 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.